Literature DB >> 6129936

Tissue and bacterial splitting of sulphasalazine.

A K Azad Khan, G Guthrie, H H Johnston, S C Truelove, D H Williamson.   

Abstract

1. The cleavage of sulphasalazine at the azo bond by bacterial suspensions and tissue homogenates has been studied in vitro. 2. For maximum activity the azo reductase system requires anaerobic conditions and the presence of cofactors, namely NADPH and FAD. In this respect, sulphasalazine resembles other azo dyes. 3. Under optimum conditions all the species of bacteria tested were capable of splitting sulphasalazine and there were no major differences in the degree of activity shown by different species. The enzyme system is located within the bacterial cell and does not leak out of it. 4. All the tissues tested, both human and rat, showed azo reductase activity. The liver showed a much higher activity than the other tissues.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6129936     DOI: 10.1042/cs0640349

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  10 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  Pharmacokinetics of sulfasalazine metabolites in rats following concomitant oral administration of riboflavin.

Authors:  V S Chungi; L W Dittert; L Shargel
Journal:  Pharm Res       Date:  1989-12       Impact factor: 4.200

3.  Mycobacterium tuberculosis-Induced Upregulation of the COX-2/mPGES-1 Pathway in Human Macrophages Is Abrogated by Sulfasalazine.

Authors:  Wenfei Wang; Yuping Ning; Yejun Wang; Guofang Deng; Simona Pace; Stefanie A Barth; Christian Menge; Kehong Zhang; Youchao Dai; Yi Cai; Xinchun Chen; Oliver Werz
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

Review 4.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

5.  The relation between swelling properties and enzymatic degradation of azo polymers designed for colon-specific drug delivery.

Authors:  G Van den Mooter; C Samyn; R Kinget
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

Review 6.  Comparative tolerability of therapies for ulcerative colitis.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 7.  Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease.

Authors:  R Luqmani; C Gordon; P Bacon
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 8.  Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

9.  Gut microbiota-driven drug metabolism in inflammatory bowel disease.

Authors:  Femke Crouwel; Hans J C Buiter; Nanne K de Boer
Journal:  J Crohns Colitis       Date:  2020-07-11       Impact factor: 9.071

10.  A novel approach for the prediction of species-specific biotransformation of xenobiotic/drug molecules by the human gut microbiota.

Authors:  Ashok K Sharma; Shubham K Jaiswal; Nikhil Chaudhary; Vineet K Sharma
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.